FDA approves Spriaso’s NDA for codeine antitussive with anti-histamine
Jointly developed with Nexgen Pharma, Tuxarin ER will be the first product to provide long lasting cough suppression with a safer opiate that is less prone to respiratory
Jointly developed with Nexgen Pharma, Tuxarin ER will be the first product to provide long lasting cough suppression with a safer opiate that is less prone to respiratory
The NIH grant of $299,585 is for the first year of a two-year project period beginning this July. The grant will be used to support the preclinical testing
The tablet combines Gilead’s emtricitabine 200mg and tenofovir alafenamide (TAF) 25mg with Janssen Sciences Ireland’s rilpivirine 25mg (R/F/TAF). The company said that the data submitted in the NDA
DE-122 is the ophthalmic formulation of Santen’s partner Tracon Pharmaceuticals’ anti-endoglin antibody, TRC105. In March last year, Santen licensed the global rights for the development of TRC105 in
AV-101 is a clinical-stage prodrug candidate that readily gains access to the central nervous system (CNS) after systemic administration and is rapidly converted in vivo to its active
The decision to cease distribution follows a negative outcome of price negotiations with the GKV-Spitzenverband, the German national association of statutory health insurance funds. Tresiba provides an ultra-long
The acquisition will expand AMAG’s suite of maternal health business and add improved commercial capabilities as well as future growth opportunities to its portfolio. CBR’s storage facility houses
Vibativ is a bactericidal, once-daily antibiotic with in vitro potency and a dual mechanism of action against Gram-positive bacteria. Russian pharmaceutical firm R-Pharm will be responsible to market
The company said that the EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the National Institutes of Health (NIH) to develop the program from the preclinical
The company has completed enrollment and dosing in a Phase I clinical trial of Aerucin and the results are expected to be reported in the fourth quarter of